IHS Chemical Week

EnviroTech :: Biotech

Merck & Co. and Hanwha Chemical to Develop Biosimilar Candidate

12:03 AM MDT | June 14, 2011 | Deepti Ramesh

Merck & Co. (Whitehouse Station, NJ) says it has entered into an exclusive global agreement with Hanwha Chemical (Seoul) to develop and commercialize a candidate biosimilar form of Enbrel (etanercept). Hanwha Chemical, through its Bio business unit, and Merck, through a subsidiary, will work together to develop and commercialize HD203, a candidate biosimilar form of etanercept developed by Hanwha, under the terms of the agreement. Merck will conduct clinical development and be responsible for manufacturing. Merck will commercialize HD203 globally, except for...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa